Curative Biosciences (BEVS) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BEVS Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Curative Biosciences balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2018)
(Dec 31 2017) (Sep 30 2017) (Jun 30 2017) (Mar 31 2017)
Assets
Cash & cash equivalent0.00
Cash & Short-term Investments0.00
Total Current Assets0.00
Equipment/Property/Plant Net0.00
Intangible Assets0.01
Total Assets0.01
Liabilities
Accounts Payable, Current AC0.17
Accrued Liabilities, Current AC0.01
Estimated Litigation Liability, Current0.20
Loans Payable, Current NO0.16
Other Liabilities, Current0.19
Sales and Excise Tax Payable, Current0.00
Total Current Liabilities0.72
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Total Liabilities0.72
Stockholders' Equity
Common Stock Value0.02
Additional Paid In Capital Common Stock52.94
Retained Earnings / Accumulated Deficit-53.66
Other Equity0.00
Common Stockholder's Equity-0.71
Total Stockholder's Equity-0.71
Liabilities & Stockholder's Equity0.01
4 historic quarters locked

Sign in to unlock the full Curative Biosciences balance sheet history.

About BEVS Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.